Download PDF
Drug Res (Stuttg) 2013; 63(10): 540-544
DOI: 10.1055/s-0033-1347240
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

Pharmacokinetics, Distribution and Excretion of PNA in Rat by Liquid Chromatography Mass Spectrometry Method

X. Huang
1   Jiangsu Center for Drug Screening, China Pharmaceutical University, Nanjing, P. R. China
2   Key Laboratory of Drug Quality Control and Pharmacovigilance, China Pharmaceutical University, Ministry of Education, Nanjing, P. R. China
,
Z.-Z. Jiang
1   Jiangsu Center for Drug Screening, China Pharmaceutical University, Nanjing, P. R. China
,
T. Wang
1   Jiangsu Center for Drug Screening, China Pharmaceutical University, Nanjing, P. R. China
,
Z. Li
1   Jiangsu Center for Drug Screening, China Pharmaceutical University, Nanjing, P. R. China
,
L.-Y. Zhang
1   Jiangsu Center for Drug Screening, China Pharmaceutical University, Nanjing, P. R. China
,
Z.-J. Zhang
2   Key Laboratory of Drug Quality Control and Pharmacovigilance, China Pharmaceutical University, Ministry of Education, Nanjing, P. R. China
› Author Affiliations
Further Information

Publication History

received 25 April 2013

accepted 11 May 2013

Publication Date:
21 June 2013 (online)

Also available at
    Permissions and Reprints

Corrected by:

Pharmacokinetics, Distribution and Excretion of PNA in Rat by Liquid Chromatography Mass Spectrometry MethodDrug Res (Stuttg) 2013; 63(12): 662-662
DOI: 10.1055/s-0033-1358701

Abstract

The pharmacokinetic profiles, tissue distribution and excretion patterns of PNA in healthy male and female Sprague-Dawley rats following a single intra-duodenum administration were investigated by previously established LC-MS method. Absorption was rapid in rats as evidenced by a short time to maximum concentration (Cmax) of 0.050±0.021, 0.072±0.017 and 0.067±0.018 h at the 25, 50 and 100 mg/kg dose level, respectively. The Cmax were 754.9±196.1, 1187.8±642.1 and 2082.1±1278.5 ng/mL and the AUC0-4 were 71.8±25.9, 135.2±69.9 and 303.3±198.3 µg/L*h, which showed linear with the intra-duodenum administration range from 25–100 mg/kg. Tissues were collected at 4 time points (3, 10 min, 1 and 3 h) after dosing at 50 mg/kg. Compare to the concentrations of plasma and other tissues, the level was particularly high in the liver and brain during 3 h. Bile/urine and feces samples were collected before dosing and till 24/48 h post-dosing. The mean cumulative excretion of unchanged PNA in bile amounted to 0.021% of the dose up to 24 h. The mean recoveries of unchanged PNA were 0.0095% and 0.043% of the dose up to 48 h in urine and feces, respectively. There was no significant difference in PNA concentration observed between male and female rats during the experiments.

Key words

liquid chromatography/mass spectrometry - PNA - pharmacokinetics - tissue distribution - excretion
 

  • References

  • 1 Hu P, Jiang J, Wang H et al. Single-dose and multiple-dose pharmacokinetics and safety of telbivudine after oral administration in healthy Chinese subjects. J Clin Pharmacol 2006; 46: 999-1007
    CrossrefPubMedGoogle Scholar
  • 2 Mohamed R, Desmond P, Suh DJ et al. Practical difficulties in the management of hepatitis B in the Asia-Pacific region. J Gastroenterol Hepatol 2004; 19: 958-969
    CrossrefPubMedGoogle Scholar
  • 3 Merican I, Guan R, Amarapuka D et al. Chronic hepatitis B virus infection in Asian countries. J Gastroenterol Hepatol 2000; 18: 1356-1361
    PubMedGoogle Scholar
  • 4 Wenting Z, Mengxiang N, Shaotan Z. Review of anti-virus agent of nucleosides. Anti infection pharmacy 2005; 2: 55-59
    PubMedGoogle Scholar
  • 5 Zhou XJ, Fielman BA, Lloyd DM et al. Pharmacokinetics of telbivudine in healthy subjects and absence of drug interaction with lamivudine or adefovir dipivoxil. Antimicrobial Agents And Chemotherapy 2006; 50: 2309-2315
    CrossrefPubMedGoogle Scholar
  • 6 Yan JH, Bifano M, Olsen S et al. Entecavir pharmacokinetics, safety and tolerability after multiple ascending doses in healthy subjects. J Clin Pharmacol 2006; 46: 1250-1258
    CrossrefPubMedGoogle Scholar
  • 7 Min AD, Dienstag JL. Oral antivirals for chronic hepatitis B. Clin Liver Dis 2007; 11: 851-868
    CrossrefPubMedGoogle Scholar
  • 8 Ferreira MS, Borges AS. Advances in the treatment of hepatitis B. Rev Soc Bras Med Trop 2007; 40: 451-462
    CrossrefPubMedGoogle Scholar
  • 9 Foster Wendy K, Miller Darren S, Scougall Catherine A et al. Effect of Antiviral Treatment with Entecavir on Age- and Dose-Related Outcomes of Duck Hepatitis B Virus Infection. Foreign Medical Sciences Section on Pharmacy 2004; 31: 366-369
    PubMedGoogle Scholar
  • 10 Li Z, Huang X, Jiang Z et al. A sensitive and specific liquid chromato­graphy – mass spectrometry method for determination of metacavir in rat plasma. Journal of Chromatography B. 2008; 864: 9-14
    CrossrefPubMedGoogle Scholar